Press Releases
-
Aug 9, 2004
Second Quarter GAAP Net Loss of $0.86 Per Share and Pro Forma Adjusted Net Loss of $0.28 Per ShareBioMarin Pharmaceutical Inc. today announced financial results for the second quarter of the fiscal year 2004. The company incurred a GAAP net loss of $55.6 million ($0.86 per share) for the...
-
Jul 19, 2004Study Demonstrates Substantial Reduction in Phenylalanine Levels in PKU Patients
BioMarin Pharmaceutical Inc. announced positive results from a pilot clinical study of 6R-BH4 in 20 patients with phenylketonuria (PKU). 6R-BH4 is the active agent in Phenoptin(TM), an...
-
Jun 2, 2004Aryplase Demonstrates Statistically Significant Benefit in Primary Endpoint
BioMarin Pharmaceutical Inc. today announced positive results from its Phase 3 clinical trial of Aryplase(TM), an investigational enzyme replacement therapy for the treatment of...
-
May 18, 2004
BioMarin Pharmaceutical Inc. announced that it has completed the transaction, announced April 20, 2004, to obtain Ascent Pediatrics, a profitable pediatrics business that includes Orapred(R), the...
-
May 3, 2004Conference Call and Webcast to be Held Today at 12:00 p.m. EDT (18:00 CEST)
BioMarin Pharmaceutical Inc. today announced financial results for the first quarter of the fiscal year 2004. The company incurred a net loss of $19.9 million ($0.31 per share) for the quarter...
-
Apr 20, 2004Ascent Pediatrics, Inc. Provides BioMarin with Growing Product Revenues and Commercial Infrastructure to Launch its Pipeline of Pediatric Products
BioMarin Pharmaceutical Inc. today announced that it has signed definitive agreements with Medicis Pharmaceutical Corporation to obtain its Pediatric Business as defined in the transaction...
-
Dec 29, 2003
Patients receiving protein-based biopharmaceuticals may eventually benefit from a technology to improve their immune tolerance to such treatments, according to early stage research to be published...
-
Nov 19, 2003BioMarin Accelerates Development of Phenoptin, a Novel Oral Enzyme Cofactor for the Treatment of PKUIf Approved, Phenoptin Could Become the First Prescription Drug for the Treatment of PKU
BioMarin Pharmaceutical Inc. announced plans to begin clinical trials with Phenoptin(TM), an enzyme cofactor that is a second generation, proprietary oral form of tetrahydrobiopterin, for the...
-
Nov 5, 2003BioMarin on Track to File for US and EU Marketing Authorization in 2004 Pending Positive Results from the Ongoing Phase 3 Study
BioMarin Pharmaceutical Inc. announced positive long-term results from Phase 1 and Phase 2 clinical studies of Aryplase(TM), an investigational enzyme replacement therapy for the treatment of...
-
Nov 3, 2003Conference Call and Webcast to be Held Today at 12:00 PM ET (18:00 CET)
BioMarin Pharmaceutical Inc. today announced financial results for its third quarter ended September 30, 2003. The net loss was $21.3 million ($0.33 per share) for the third quarter of 2003...
-
Sep 21, 2003BioMarin Spending Projected to Decrease in Both 2003 and 2004
BioMarin Pharmaceutical Inc. announced that it halted its Phase 3a study of Neutralase(TM) for the reversal of anticoagulation by heparin in primary Coronary Artery Bypass Graft (CABG) surgery and...
-
Sep 3, 2003Data Warrants Further Study of Intrathecal Injection of Enzyme for Treating Neurological Symptoms of MPS I
BioMarin Pharmaceutical Inc. announced results from studies indicating that intrathecal injection of recombinant human alpha-L-iduronidase (rhIDU) can reduce carbohydrate storage in brain tissue...
